This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
July and August saw key regulatory and clinical developments for several anti-PD-(L)1 MAbs, with plenty more in store for oncology watchers.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
But a lacklustre pipeline could stoke the need for deals.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.